Adverum Biotechnologies Yönetim
Yönetim kriter kontrolleri 4/4
Adverum Biotechnologies' CEO is Laurent Fischer, appointed in Jun 2020, has a tenure of 4.42 years. total yearly compensation is $1.55M, comprised of 43.4% salary and 56.6% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $521.76K. The average tenure of the management team and the board of directors is 2.8 years and 4.5 years respectively.
Anahtar bilgiler
Laurent Fischer
İcra Kurulu Başkanı
US$1.5m
Toplam tazminat
| CEO maaş yüzdesi | 43.4% |
| CEO görev süresi | 4.4yrs |
| CEO sahipliği | 0.3% |
| Yönetim ortalama görev süresi | 2.8yrs |
| Yönetim Kurulu ortalama görev süresi | 4.5yrs |
Son yönetim güncellemeleri
Recent updates
We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Feb 24
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
Sep 07Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10
Aug 11Adverum gains 13% to reach three-month high after Truist upgrade
Jul 07We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
May 12We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Jul 17Adverum Biotechnologies: An Uncertain Path Forward
May 05Adverum Bio presents long-term data from ADVM-022 trial in wet AMD
May 03We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Apr 06Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
Feb 13
Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy
Feb 02Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares
Jan 22Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market
Jan 11Adverum Biotechnologies announces new GMP gene therapy manufacturing facility
Jan 07How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?
Dec 31CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$100m |
| Mar 31 2024 | n/a | n/a | -US$113m |
| Dec 31 2023 | US$2m | US$672k | -US$117m |
| Sep 30 2023 | n/a | n/a | -US$126m |
| Jun 30 2023 | n/a | n/a | -US$133m |
| Mar 31 2023 | n/a | n/a | -US$146m |
| Dec 31 2022 | US$3m | US$646k | -US$155m |
| Sep 30 2022 | n/a | n/a | -US$156m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$155m |
| Dec 31 2021 | US$9m | US$621k | -US$146m |
| Sep 30 2021 | n/a | n/a | -US$149m |
| Jun 30 2021 | n/a | n/a | -US$138m |
| Mar 31 2021 | n/a | n/a | -US$123m |
| Dec 31 2020 | US$22m | US$327k | -US$118m |
Tazminat ve Piyasa: Laurent's total compensation ($USD1.55M) is about average for companies of similar size in the US market ($USD1.48M).
Tazminat ve Kazançlar: Laurent's compensation has been consistent with company performance over the past year.
CEO
Laurent Fischer (60 yo)
4.4yrs
Görev süresi
US$1,546,477
Tazminat
Dr. Laurent Fischer, M.D., serves as Chair of the Board of Teal Omics Inc. He has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He is Advisor of FORM Life Ventures. He...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 4.4yrs | US$1.55m | 0.34% $ 521.8k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 1.9yrs | US$2.30m | 0.048% $ 74.1k | |
| Chief Operating Officer | 3.4yrs | US$903.02k | 0.13% $ 205.9k | |
| Chief Development Officer | 2.8yrs | US$799.36k | 0.026% $ 39.8k | |
| Chief Medical Officer | less than a year | US$94.20k | 0% $ 0 | |
| Chief Technology Officer | 1.3yrs | Veri yok | Veri yok | |
| Chief Scientific Officer | less than a year | Veri yok | Veri yok | |
| Senior VP & General Counsel | 3.3yrs | US$1.33m | 0.031% $ 48.0k | |
| Chief People Officer | 5.3yrs | Veri yok | Veri yok | |
| Senior Vice President of Regulatory Affairs | 2.8yrs | Veri yok | Veri yok | |
| Senior Vice President of Quality | 3.1yrs | Veri yok | Veri yok | |
| Senior VP of Manufacturing & Supply Chain Management and Head of Technical Operations | no data | Veri yok | Veri yok |
2.8yrs
Ortalama Görev Süresi
56.5yo
Ortalama Yaş
Deneyimli Yönetim: ADVM's management team is considered experienced (2.8 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 4.4yrs | US$1.55m | 0.34% $ 521.8k | |
| Independent Director | 5.5yrs | US$111.70k | 0.050% $ 76.6k | |
| Independent Director | 4.6yrs | US$106.70k | 0% $ 0 | |
| Scientific Advisory Board Member | no data | Veri yok | Veri yok | |
| Independent Chairman | 7.7yrs | US$163.80k | 0.042% $ 65.3k | |
| Scientific Advisory Board Member | no data | Veri yok | Veri yok | |
| Independent Director | 3.8yrs | US$99.20k | 0% $ 0 | |
| Independent Director | 3.9yrs | US$106.70k | 0.024% $ 37.1k | |
| Independent Director | 5.5yrs | US$99.20k | 0.063% $ 96.3k | |
| Scientific Advisory Board Member | no data | Veri yok | Veri yok | |
| Scientific Advisory Board Member | no data | Veri yok | Veri yok | |
| Director | less than a year | Veri yok | Veri yok |
4.5yrs
Ortalama Görev Süresi
63yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ADVM's board of directors are considered experienced (4.5 years average tenure).